HIGHLIGHTS
- What: The authors aimed to identify putative therapeutic targets through systematic bioinformatic analysis of PRCC with fusion.
- Who: RNA-Seq and colleagues from the Medical Research Collaborating Center, Seoul National University Bundang have published the paper: Target-based drug repositioning in papillary renal cell carcinoma with TFE3 fusion, in the : Proceedings of the 4th International Conference on Biological Engineering and Medical Science
- How: This study not only depicts the landscape of the overall cell signaling and key genes in TFE3 fusion-positive RCC but also provides baseline data that can be used to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.